#USA #Washington #LSPedia #OneScan #Serialized Recall

LSPedia's Serialized Recall Management Module

On August 5, 2025, at the Healthcare Distribution Alliance's Annual Traceability Seminar, LSPedia unveiled its latest innovation—the Serialized Recall Management Module. This revolutionary tool is set to transform the pharmaceutical landscape, particularly regarding the automation of recalls and enhancing patient safety.

Setting a New Standard

LSPedia, a recognized leader in pharmaceutical serialization and supply chain technology, has established new expectations for handling drug recalls. The Serialized Recall Management Module, an extension of their OneScan® platform, simplifies the recall process by addressing critical issues faced in the pharmaceutical sector. By implementing smarter workflows, LSPedia aims to minimize manual labor, streamline communication, and reduce complexities that have historically burdened the recall process.

In an age where efficiency is paramount, LSPedia’s module promises to slash recall notification times significantly—potentially by up to 90%—while also decreasing manual labor hours by nearly the same percentage. This module not only mitigates risks but also enhances overall operational value, thus fostering greater trust amongst both pharmaceutical companies and their patient communities.

The Tech Behind the Innovation

The core of the Serialized Recall Management Module lies in its ability to harness serialized data. This capability allows manufacturers, distributors, and dispensers to easily identify affected products down to their specific lot and serial numbers. With real-time notifications sent to impacted stakeholders, the management of recalls becomes more precise and efficient. Key features of the module include:

• - Ambient Listening using AI/ML: Detects potential recall triggers effectively.
• - Automated Recall Initiation: Seamlessly integrates with EPCIS transactions for smoother operations.
• - Targeted Notifications: Instant alerts to distribution centers and downstream customers to ensure swift responses.
• - End-to-End Reconciliation: Provides visibility at the location level, ensuring accountability throughout the supply chain.
• - Integrated Return Logistics (Recall+): Employs sophisticated data exchange mechanisms for labels, shipping, and decommissioning.

A Vision for the Future

Riya Cao, CEO of LSPedia, expressed her excitement about the future of the pharmaceutical industry in the AI era, stating, “In the age of AI, there's no reason drug recalls should still be mired in paperwork, confusion, and delay.” The implementation of the Serialized Recall Module not only simplifies the complex nature of recalls but also empowers pharmaceutical companies to build adaptable and resilient supply chains.

Cao adds, “Serialized Recall isn’t just built with AI; it enables AI at scale, powering a smarter and faster supply chain.” This perspective aligns with the competitive nature of the pharmaceutical industry, where staying ahead in technology is crucial for survival and success.

Availability and Future Plans

For those eager to adopt this upgrade, the Serialized Recall Management Module will be available to early adopters starting in August 2025, with a broader rollout anticipated in October 2025. Additionally, LSPedia will introduce an enhanced version—Recall+—that promises comprehensive automation through the OneScan Enterprise platform. This version is expected to enter early access in the first quarter of 2026.

Adam Moy, CTO of LSPedia, stated, “Our Serialized Recall Management Module is destined to become the gold standard for drug recall systems. It is a vital capability for a modern, digital, and intelligent pharmaceutical supply chain.”

LSPedia’s ongoing commitment to digital transformation and AI-driven compliance innovation reaffirms its leadership position in serialized operations, ensuring that the pharmaceutical industry can operate faster, smarter, and ultimately better serve patients.

For more information or to request a demo, visit LSPedia's website or reach out to their media contact, Eric Kushner at [email protected].